Journal Article
. 2014 Sep;148(1).
doi: 10.1007/s10549-014-3143-z.

Can mammographic and sonographic imaging features predict the Oncotype DX™ recurrence score in T1 and T2, hormone receptor positive, HER2 negative and axillary lymph node negative breast cancers?

Monica Maria Yepes 1 Ada Pat Romilly  Fernando Collado-Mesa  Jose Miguel Net  Richard Kiszonas  Kristopher L Arheart  Daniel Young  Stefan Glück  
Affiliations
  • PMID: 25262341
  •     8 citations

Abstract

To determine whether mammographic or sonographic features can predict the Oncotype DX™ recurrence scores (RS) in patients with TI-II, hormone receptor (HR) positive, HER2/neu negative and node negative breast cancers. Institutional board review was obtained and informed consent was waived for this retrospective study. Seventy-eight patients with stage I-II invasive breast cancer that was HR positive, HER2 negative, and lymph node negative for whom mammographic and or sonographic imaging and Oncotype DX™ assay scores were available were included in the study Four breast dedicated radiologists blinded to the RS retrospectively described the lesions according to BI-RADS lexicon descriptors. Multivariable logistic regression was used to test for significant independent predictors of low (<18) versus intermediate to high range (≥18). Two imaging features reached statistical significance in predicting low from intermediate or high risk RS: pleomorphic microcalcifications within a mass (P = 0.017); OR 8.37, 95 % CI (1.47-47.79) on mammography and posterior acoustic enhancement in a mass on ultrasound (P = 0.048); OR 4.35, 95 % CI (1.01-18.73) on multivariable logistic regression. A mass with pleomorphic microcalcifications on mammography or the presence of posterior acoustic enhancement on ultrasound may predict an intermediate to high RS as determined by the Oncotype DX(TM) assay in patients with stage I-II HR positive, HER2 negative, and lymph node negative invasive breast cancer.

Association between partial-volume corrected SUVmax and Oncotype DX recurrence score in early-stage, ER-positive/HER2-negative invasive breast cancer.
Su Hyun Lee, Seunggyun Ha, +9 authors, Gi Jeong Cheon.
Eur J Nucl Med Mol Imaging, 2016 May 23; 43(9). PMID: 27209424
Association between Ultrasound Features and the 21-Gene Recurrence Score Assays in Patients with Oestrogen Receptor-Positive, HER2-Negative, Invasive Breast Cancer.
Eun Young Chae, Woo Kyung Moon, +8 authors, Sei Hyun Ahn.
PLoS One, 2016 Jul 01; 11(6). PMID: 27362843    Free PMC article.
Molecular subtypes and imaging phenotypes of breast cancer.
Nariya Cho.
Ultrasonography, 2016 Sep 08; 35(4). PMID: 27599892    Free PMC article.
Review.
Apparent diffusion coefficient in estrogen receptor-positive and lymph node-negative invasive breast cancers at 3.0T DW-MRI: A potential predictor for an oncotype Dx test recurrence score.
Sunitha B Thakur, Manuela Durando, +5 authors, Elizabeth A Morris.
J Magn Reson Imaging, 2017 Jun 24; 47(2). PMID: 28640531    Free PMC article.
Gene expression profiling of calcifications in breast cancer.
Sung Ui Shin, Jeonghoon Lee, +7 authors, Woo Kyung Moon.
Sci Rep, 2017 Sep 14; 7(1). PMID: 28900139    Free PMC article.
Radiogenomics analysis identifies correlations of digital mammography with clinical molecular signatures in breast cancer.
Jose-Gerardo Tamez-Peña, Juan-Andrés Rodriguez-Rojas, +6 authors, Victor Treviño.
PLoS One, 2018 Mar 30; 13(3). PMID: 29596496    Free PMC article.
Sonography with vertical orientation feature predicts worse disease outcome in triple negative breast cancer.
Haoyu Wang, Weiwei Zhan, +3 authors, Kunwei Shen.
Breast, 2019 Nov 05; 49. PMID: 31677531    Free PMC article.
Imaging features of breast cancer molecular subtypes: state of the art.
Nariya Cho.
J Pathol Transl Med, 2020 Nov 07; 55(1). PMID: 33153242    Free PMC article.
Review.